摘要
目的探讨S100A13、FGF-1在甲状腺癌中的表达及其临床意义。方法采用免疫组织化学法,检测56例甲状腺癌、15例甲状腺腺瘤、14例甲状腺正常组织中S100A13及FGF-1的表达。结果S100A13与FGF-1阳性染色定位于细胞质。S100A13在少部分腺瘤和正常组织中阳性染色定位于细胞核。S100A13表达阳性率分别为甲状腺癌91.1%、甲状腺腺瘤66.7%、甲状腺正常组织64.3%;FGF-1表达阳性率分别为89.3%、60.0%、57.1%;甲状腺癌与其他各组比较均有显著性差异(P<0.05)。FGF-1在乳头状癌中阳性表达率(100.0%)显著高于髓样癌(69.2%)(P<0.05)。结论联合检测S100A13与FGF-1表达对鉴别甲状腺癌具有重要意义,两者表达水平可能与甲状腺癌的发生及转移相关。
Objective To investigate the expression and clinical significance of S100A13 and FGF-1 in the thyroid carcinoma. Methods The expression of S100A13 and FGF-1 was detected by immunohistochemistry in 71 cases with thyroid tumor （56 carcinomas and 15 adenomas） and 14 of normal thyroid. Results The positive rate of S100A13 was 91.1% in thyroid carcinoma,66.7% in thyroid adenoma and 64.3% in normal thyroid tissues. The positive rate of FGF-1 was 89.3% ,60.0% ,57.1% respectively. The expression of S100A13 and FGF-1 in thyroid carcinoma was significantly higher than that in adenomas and normal tissues（P 〈 0.05 ）. The positive rate of FGF-1 in papillary cancer （ 100.0% ） is higher than that in medullary cancer （69.2 % ） （P 〈 0.05）. Conclusion Combined detection of the expression of S100A13 and FGF-1 may have important value in the differential diagnosis of thyroid carcinoma. The percentage of S100A13 and FGF-1 positive expression may be correlated with the carcinoma metastasis.
出处
《实用癌症杂志》
2009年第1期19-21,25,共4页
The Practical Journal of Cancer
基金
湖南省自然科学基金资助项目(05JJ30039)
湖南省医药卫生科研计划课题资助项目(B2005099)
